Welcome to Peptide Card of AntiTbPdb
This page displays user query in tabular form. |
STLHLVLRLRGG details |
Primary information | |
---|---|
ID | antitb_1302, |
Name | 19682257 |
N-Terminal modification | Ubiquitin-derived peptide (Ub2) |
C-Terminal Modification | STLHLVLRLRGG |
Chemical Modification | Free |
Linear/Cyclic | Free |
Length | None |
Chirality | Linear |
Nature | 12 |
Source | L |
Origin | Cationic |
Species | Natural |
Strain | Ubiquitin derived |
Inhibition Concentration | Mycobacterium smegmatis |
In Vitro/ In vivo | M. smegmatis mc2 155 |
Cell Line | 1.5 fold reduction in bacterial colony as compared to control at 50 μM of peptide |
Inhibition Concentration | In vitro |
Sequence | 2009 |
Cytotoxicity | NA |
In vivo Model | NA |
Lethal Dose | NA |
Immune Responce | NA |
Mechanism of Action | NA |
Target | NA |
Combination Therapy | Pore formation in Mycobacterial membrane |
Other activities | mspA gene which form porins in membrane, peptide increase the expression of this gene |
PMID | NA |
Year of Publication | NA |
Tertiary Structure (Technique) | Not Predicted), |
Primary information | |
---|---|
ID | antitb_1303, |
Name | 19682257 |
N-Terminal modification | Ubiquitin-derived peptide (Ub2) |
C-Terminal Modification | STLHLVLRLRGG |
Chemical Modification | Free |
Linear/Cyclic | Free |
Length | None |
Chirality | Linear |
Nature | 12 |
Source | L |
Origin | Cationic |
Species | Natural |
Strain | Ubiquitin derived |
Inhibition Concentration | Mycobacterium smegmatis |
In Vitro/ In vivo | M. smegmatis mc2 155 |
Cell Line | 1.5 fold reduction in bacterial colony as compared to control at 60 μM of peptide |
Inhibition Concentration | In vitro |
Sequence | 2009 |
Cytotoxicity | NA |
In vivo Model | NA |
Lethal Dose | NA |
Immune Responce | NA |
Mechanism of Action | NA |
Target | NA |
Combination Therapy | Pore formation in Mycobacterial membrane |
Other activities | mspA gene which form porins in membrane, peptide increase the expression of this gene |
PMID | NA |
Year of Publication | NA |
Tertiary Structure (Technique) | Not Predicted), |
Primary information | |
---|---|
ID | antitb_1304, |
Name | 19682257 |
N-Terminal modification | Ubiquitin-derived peptide (Ub2) |
C-Terminal Modification | STLHLVLRLRGG |
Chemical Modification | Free |
Linear/Cyclic | Free |
Length | None |
Chirality | Linear |
Nature | 12 |
Source | L |
Origin | Cationic |
Species | Natural |
Strain | Ubiquitin derived |
Inhibition Concentration | Mycobacterium smegmatis |
In Vitro/ In vivo | M. smegmatis mc2 155 |
Cell Line | 2.5 fold reduction in bacterial colony as compared to control at75 μM |
Inhibition Concentration | In vitro |
Sequence | 2009 |
Cytotoxicity | NA |
In vivo Model | NA |
Lethal Dose | NA |
Immune Responce | NA |
Mechanism of Action | NA |
Target | NA |
Combination Therapy | Pore formation in Mycobacterial membrane |
Other activities | mspA gene which form porins in membrane, peptide increase the expression of this gene |
PMID | NA |
Year of Publication | NA |
Tertiary Structure (Technique) | Not Predicted), |
Primary information | |
---|---|
ID | antitb_1305, |
Name | 19682257 |
N-Terminal modification | Ubiquitin-derived peptide (Ub2) |
C-Terminal Modification | STLHLVLRLRGG |
Chemical Modification | Free |
Linear/Cyclic | Free |
Length | None |
Chirality | Linear |
Nature | 12 |
Source | L |
Origin | Cationic |
Species | Natural |
Strain | Ubiquitin derived |
Inhibition Concentration | Mycobacterium smegmatis |
In Vitro/ In vivo | M. smegmatis mc2 155 |
Cell Line | 3 fold reduction in bacterial colony as compared to control at100 μM |
Inhibition Concentration | In vitro |
Sequence | 2009 |
Cytotoxicity | NA |
In vivo Model | NA |
Lethal Dose | NA |
Immune Responce | NA |
Mechanism of Action | NA |
Target | NA |
Combination Therapy | Pore formation in Mycobacterial membrane |
Other activities | mspA gene which form porins in membrane, peptide increase the expression of this gene |
PMID | NA |
Year of Publication | NA |
Tertiary Structure (Technique) | Not Predicted), |
Primary information | |
---|---|
ID | antitb_1540, |
Name | 25613372 |
N-Terminal modification | Ub2 |
C-Terminal Modification | STLHLVLRLRGG |
Chemical Modification | Free |
Linear/Cyclic | Free |
Length | None |
Chirality | Linear |
Nature | 12 |
Source | L |
Origin | Cationic |
Species | Protein derived |
Strain | Derived from human ubiquitin protein |
Inhibition Concentration | Mycobacterium tuberculosis |
In Vitro/ In vivo | Mycobacterium tuberculosis H37Rv |
Cell Line | MIC = 5 μg/ml |
Inhibition Concentration | in vitro |
Sequence | 2015 |
Cytotoxicity | NA |
In vivo Model | NA |
Lethal Dose | NA |
Immune Responce | NA |
Mechanism of Action | NA |
Target | NA |
Combination Therapy | Disrupt the mycobacterial membrane |
Other activities | NA |
PMID | NA |
Year of Publication | Bactericidal against pseudomonas and staphylococcus at pH 5.5 |
Tertiary Structure (Technique) | Not Predicted), |
Primary information | |
---|---|
ID | antitb_1816, |
Name | 23173767 |
N-Terminal modification | ubiquitin-derived peptide Ub2 |
C-Terminal Modification | STLHLVLRLRGG |
Chemical Modification | Free |
Linear/Cyclic | Free |
Length | None |
Chirality | Linear |
Nature | 12 |
Source | L |
Origin | Cationic |
Species | Protein Derived |
Strain | Ubiquitin derived |
Inhibition Concentration | Mycobacterium smegmatis |
In Vitro/ In vivo | Mycobacterium smegmatis mc2155 |
Cell Line | MIC = 50 μM |
Inhibition Concentration | In vitro |
Sequence | 2012 |
Cytotoxicity | None |
In vivo Model | NA |
Lethal Dose | NA |
Immune Responce | NA |
Mechanism of Action | NA |
Target | NA |
Combination Therapy | Micellar aggregate channel model |
Other activities | Cytoplasmic membrane |
PMID | NA |
Year of Publication | NA |
Tertiary Structure (Technique) | Not Predicted), |